Oral Oncology
Volume 37, Issue 1 , Pages 42-49, January 2001

Assessment of various topical oral formulations by bone marrow transplant recipients

  • L.A. Bellm

      Affiliations

    • IntraBiotics Pharmaceuticals Inc., Mountain View, CA 94043, USA
  • ,
  • J.B. Epstein

      Affiliations

    • British Columbia Cancer Agency, Vancouver Hospital and Health Sciences Centre, University of British Columbia, Vancouver, Canada
    • University of Washington, Seattle, WA, USA
  • ,
  • A.M. Rose-Ped

      Affiliations

    • Empirica Inc., Portland, OR, USA
  • ,
  • R. Fu

      Affiliations

    • IntraBiotics Pharmaceuticals Inc., Mountain View, CA 94043, USA
  • ,
  • P.J. Martin

      Affiliations

    • Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • ,
  • H.J. Fuchs

      Affiliations

    • IntraBiotics Pharmaceuticals Inc., Mountain View, CA 94043, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-650-526-6800; fax: +1-650-969-0663

Received 26 April 2000; accepted 4 May 2000.

Abstract 

Topical approaches to management of oral mucositis have the advantages of high local concentration and limited or no systemic absorption, reducing the risk of systemic complications. The acceptability of topical therapies in cancer patients has not been evaluated. Thirty-eight transplant patients assessed the acceptability of three formulations (rinse, thin gel, thick gel) of a new compound developed to prevent oral mucositis. The rinse was selected as the most acceptable formulation. The thick gel received the lowest rating. Consistency was a major determinant of overall acceptability. A neutral taste was desirable for most participants. Room temperature of the formulation was rated as completely acceptable. Most participants would be willing to use the rinse or thin gel several times per day, to retain each dose in the oral cavity for up to 5 min, and to swallow it. The support of caregivers may be needed to achieve compliance with such regimens.

Keywords:  Marrow transplantation, Mucositis, Compliance, Drug formulations

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-8375(00)00054-3

Oral Oncology
Volume 37, Issue 1 , Pages 42-49, January 2001